19:41 Fri 22 Nov 2019
Avacta Group PLC - Director/PDMR Shareholding
("
Director/PDMR Shareholdings
Dr
Following the transactions, the total beneficial interest of
Details of the full notifications received by the Company are set out below:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a) |
|
|
||||
2. |
Reason for the Notification |
|||||
a) |
Position/status |
Non-executive Director |
||||
b) |
Initial notification/Amendment |
|
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
|
|
||||
b) |
LEI |
2138009U3EG31OPMGH36 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the Financial instrument, type of instrument |
|
||||
Identification code |
GB00BYYW9G87 |
|||||
b) |
Nature of the transaction |
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information: Aggregated volume Price |
As above |
||||
e) |
Date of the transaction |
|
||||
f) |
Place of the transaction |
|
- Ends -
For further information from
|
Tel: +44 (0) 844 414 0452 |
finnCap Ltd (Nominated Adviser and Joint Broker)
|
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217
|
Turner Pope Investments (TPI)
Yellow Jersey PR (Financial Media and IR)
|
Tel: +44 (0) 203 657 0050
Tel: +44 (0)7764 947 137 Tel: +44 (0)7544 275 882
Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
|
About
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby,
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE